mrx0518
Bladder Cancer
Imperial College LondonCell therapyPhase 1/2Dormant
C
35/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 22/ 100
- Competitive Position
- 73/ 100
Competitive context
122 Active assets in the Bladder Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II G1 Therapeutics, Inc. | Phase 3 | BBB |
TRASTUZUMAB NKGen Biotech, Inc. | Phase 2 | BB |
Carboplatin G1 Therapeutics, Inc. | Phase 3 | BB |
VINBLASTINE University of Southern California | Phase 3 | BB |
Pembrolizumab Essen Biotech | Phase 3 | BB |
View all 50 →
Same molecule, other indications
mrx0518 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →